Adipose SVF Spheroid Composition for Dendritic Cell Migration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dendritic cell-based immunotherapies for cancer have low response rates due to limited migration of dendritic cells to lymph nodes and inhibition by the tumor microenvironment, necessitating a method to enhance their activation and interaction with T cells.
Innovation Solution
A composition using stromal vascular fraction (SVF) isolated from adipose tissue, which forms spheroids that express chemokines and osteopontin, promoting the migration and activation of dendritic cells, enhancing their interaction with T cells and inducing a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells are used for immunotherapy, then anti-tumor immune response is induced, but response rate remains low due to limited migration to lymph nodes
Solution Approach 1:
The patent introduces stromal cells as intermediary components that create a supportive microenvironment for dendritic cells. These stromal cells secrete chemokines (CCL19, CCL21) that act as chemical mediators to attract and guide dendritic cell migration toward lymph nodes, thereby resolving the migration capability problem without changing the dendritic cells themselves.
Solution Approach 2:
The patent changes the chemical parameter environment by introducing chemokine gradients through stromal cells. The secretion of CCL19 and CCL21 creates a chemical gradient that directs dendritic cell movement, transforming the migration issue from a cellular capability problem to an environmental guidance problem that can be solved by parameter modification.
2Reliability
If dendritic cells are injected into tumor site, then antigen presentation is enhanced, but tumor microenvironment inhibits immune response
Solution Approach 1:
Stromal cells serve as protective intermediaries that shield dendritic cells from the harmful tumor microenvironment. The stromal cells create a favorable niche that maintains dendritic cell function and promotes their maturation, allowing them to overcome the inhibitory effects of the tumor environment while maintaining their antigen presentation capability.
Solution Approach 2:
The stromal cells provide beforehand cushioning by creating a protective microenvironment before dendritic cells are exposed to the harsh tumor conditions. This pre-established supportive environment cushions the dendritic cells against inhibitory factors, allowing them to maintain their immunostimulatory function despite the challenging tumor microenvironment.
3Reliability
If stromal cells from lymph nodes are used, then dendritic cell activation is improved, but isolation is virtually impossible due to low abundance
Solution Approach 1:
The patent creates a functional copy of the lymph node stromal cell environment using adipose-derived stromal cells. While these are not the exact same cells found in lymph nodes, they replicate the essential functions (chemokine secretion, dendritic cell activation) without the isolation problems, providing a practical alternative that maintains therapeutic efficacy.
Solution Approach 2:
The patent demonstrates universality by showing that stromal cells from different tissues (adipose tissue instead of lymph nodes) can perform the same immunomodulatory functions. The adipose-derived stromal cells universally provide chemokine secretion and dendritic cell activation capabilities, making the therapy more accessible without requiring rare lymph node stromal cells.
Data Source
Figure 1a~1f
Figure 2a~2f
Figure 3a~3e
AI summary
The present disclosure relates to a composition for enhancing an immune response using the activating function of dendritic cells of a stromal vascular fraction isolated from adipose tissue, and in particular, a composition for enhancing an immune response for anti-tumor use.